Floatz logo

Pell'S Lentiviral-Based Gene-Edited Immune Cell Therapy

Follicular Lymphoma Grade 3A

Pell Bio-Med Technology Co., Ltd.Cell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

209 Active assets in the Follicular Lymphoma Grade 3A cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Pell'S Lentiviral-Based Gene-Edited Immune Cell Therapy is also rated in:

diffuse large B-cell lymphomaDormant
D
Indicative ·
30 / 100
View asset →
large B-cell lymphomaDormant
D
Indicative ·
30 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →